生物制剂在膜性肾病治疗中的应用
Application of Biological Agents in the Treatment of Membranous Nephropathy
DOI: 10.12677/jcpm.2025.43357, PDF,    科研立项经费支持
作者: 林馨怡：济宁医学院临床医学院，山东 济宁；魏明明*：济宁医学院附属医院肾内科，山东 济宁
关键词: 膜性肾病；生物制剂；作用机制；淋巴细胞；补体；临床应用；Membranous Nephropathy； Biologics； Mechanism； Lymphocyte； Complement； Clinical Application
摘要: 膜性肾病是一种常见的肾小球疾病，其治疗一直是临床关注的焦点。随着对新型足细胞抗原的特异性自身抗体及膜性肾病致病途径的进一步探索，对MN的理解也随之不断发展，除了现在使用的一线生物制剂利妥昔单抗外，新型抗B细胞、抗补体和抗浆细胞等新型生物制剂的应用也在逐渐受到关注。本文阐述了生物制剂在膜性肾病治疗中的研究应用现状，包括其作用机制、疗效等方面，并对其未来的发展前景进行了展望。
Abstract: Membranous nephropathy is a common glomerular disease, and its treatment has always been the focus of clinical attention. With the further exploration of the specific autoantibodies of new podocyte antigens and the pathogenic pathways of membranous nephropathy, the understanding of MN has also been continuously developed. In addition to the current first-line biological agent rituximab, the application of new biological agents such as new anti-B cells, anti-complement and anti-plasma cells is also gradually receiving attention. This article describes the research and application status of biological agents in the treatment of membranous nephropathy, including its mechanism of action, efficacy, etc., and prospects for its future development.
文章引用：林馨怡, 魏明明. 生物制剂在膜性肾病治疗中的应用[J]. 临床个性化医学, 2025, 4(3): 385-392. https://doi.org/10.12677/jcpm.2025.43357

参考文献

[1] Sethi, S. (2021) Membranous Nephropathy: A Single Disease or a Pattern of Injury Resulting from Different Diseases. Clinical Kidney Journal, 14, 2166-2169. [Google Scholar] [CrossRef] [PubMed]
[2] Cai, Q. and Hendricks, A.R. (2020) Membranous Nephropathy: A Ten-Year Journey of Discoveries. Seminars in Diagnostic Pathology, 37, 116-120. [Google Scholar] [CrossRef] [PubMed]
[3] Couser, W.G. (2017) Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 12, 983-997. [Google Scholar] [CrossRef] [PubMed]
[4] Schieppati, A., Mosconi, L., Perna, A., Mecca, G., Bertani, T., Garattini, S., et al. (1993) Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. New England Journal of Medicine, 329, 85-89. [Google Scholar] [CrossRef] [PubMed]
[5] Jha, V., Ganguli, A., Saha, T.K., Kohli, H.S., Sud, K., Gupta, K.L., et al. (2007) A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 18, 1899-1904. [Google Scholar] [CrossRef] [PubMed]
[6] Cantarelli, C., Jarque, M., Angeletti, A., Manrique, J., Hartzell, S., O’Donnell, T., et al. (2020) A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients. Kidney International Reports, 5, 1764-1776. [Google Scholar] [CrossRef] [PubMed]
[7] Kuroki, A., Iyoda, M., Shibata, T. and Sugisaki, T. (2005) Th2 Cytokines Increase and Stimulate B Cells to Produce IgG4 in Idiopathic Membranous Nephropathy. Kidney International, 68, 302-310. [Google Scholar] [CrossRef] [PubMed]
[8] Ronco, P., Beck, L., Debiec, H., Fervenza, F.C., Hou, F.F., Jha, V., et al. (2021) Membranous Nephropathy. Nature Reviews Disease Primers, 7, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[9] So, B.Y.F., Yap, D.Y.H. and Chan, T.M. (2021) B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management. International Journal of Molecular Sciences, 22, Article 13560. [Google Scholar] [CrossRef] [PubMed]
[10] Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., et al. (1994) Depletion of B Cells in Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20. Blood, 83, 435-445. [Google Scholar] [CrossRef] 
[11] Banchereau, J. and Rousset, F. (1992) Human B Lymphocytes: Phenotype, Proliferation, and Differentiation. Advances in Immunology, 52, 125-262. [Google Scholar] [CrossRef] [PubMed]
[12] Boross, P. and Leusen, J.H. (2012) Mechanisms of Action of CD20 Antibodies. American Journal of Cancer Research, 2, 676-690.
[13] Weiner, G.J. (2010) Rituximab: Mechanism of Action. Seminars in Hematology, 47, 115-123. [Google Scholar] [CrossRef] [PubMed]
[14] Rosenzwajg, M., Languille, E., Debiec, H., Hygino, J., Dahan, K., Simon, T., et al. (2017) B-and T-Cell Subpopulations in Patients with Severe Idiopathic Membranous Nephropathy May Predict an Early Response to Rituximab. Kidney International, 92, 227-237. [Google Scholar] [CrossRef] [PubMed]
[15] Kattah, A.G. and Fervenza, F.C. (2012) Rituximab: Emerging Treatment Strategies of Immune-Mediated Glomerular Disease. Expert Review of Clinical Immunology, 8, 413-421. [Google Scholar] [CrossRef] [PubMed]
[16] Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A.N., et al. (2011) Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. Science Translational Medicine, 3, 85ra46. [Google Scholar] [CrossRef] [PubMed]
[17] Takahashi, Y., Ikezumi, Y. and Saitoh, A. (2016) Rituximab Protects Podocytes and Exerts Anti‐Proteinuric Effects in Rat Adriamycin‐Induced Nephropathy Independent of B‐Lymphocytes. Nephrology, 22, 49-57. [Google Scholar] [CrossRef] [PubMed]
[18] Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., et al. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276. [Google Scholar] [CrossRef] [PubMed]
[19] Hoxha, E., Thiele, I., Zahner, G., Panzer, U., Harendza, S. and Stahl, R.A.K. (2014) Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 25, 1357-1366. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, S., Huang, J., Dong, J., Li, Z., Sun, M., Sun, Y., et al. (2023) Efficacy and Safety of Rituximab for Primary Membranous Nephropathy with Different Clinical Presentations: A Retrospective Study. Frontiers in Immunology, 14, Article 1156470. [Google Scholar] [CrossRef] [PubMed]
[21] Gauckler, P., Shin, J.I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., et al. (2021) Rituximab in Membranous Nephropathy. Kidney International Reports, 6, 881-893. [Google Scholar] [CrossRef] [PubMed]
[22] Fervenza, F.C., Appel, G.B., Barbour, S.J., Rovin, B.H., Lafayette, R.A., Aslam, N., et al. (2019) Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 381, 36-46. [Google Scholar] [CrossRef] [PubMed]
[23] 刘纯玲, 王述蔷, 耿晓东, 等. 利妥昔单抗或他克莫司联合糖皮质激素治疗特发性膜性肾病的疗效比较[J]. 临床肾脏病杂志, 2019, 19(6): 421-425.
[24] Zhong, H., Li, H., Zhou, T. and Zhong, Z. (2020) Clinical Efficacy and Safety of Rituximab with Membranous Nephropathy: A Meta-Analysis. Archives of Medical Science, 19, 411-419. [Google Scholar] [CrossRef] [PubMed]
[25] Sanford, M. and McCormack, P.L. (2010) Ofatumumab. Drugs, 70, 1013-1019. [Google Scholar] [CrossRef] [PubMed]
[26] Lin, T. (2010) Ofatumumab: A Novel Monoclonal Anti-CD20 Antibody. Pharmacogenomics and Personalized Medicine, 3, 51-59. [Google Scholar] [CrossRef] [PubMed]
[27] Podestà, M.A., Trillini, M., Portalupi, V., Gennarini, A., Tomatis, F., Villa, A., et al. (2024) Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients with Primary Membranous Nephropathy: A Case Series. American Journal of Kidney Diseases, 83, 340-349.e1. [Google Scholar] [CrossRef] [PubMed]
[28] Patz, M., Isaeva, P., Forcob, N., Müller, B., Frenzel, L.P., Wendtner, C., et al. (2010) Comparison of the in Vitro Effects of the Anti‐CD20 Antibodies Rituximab and GA101 on Chronic Lymphocytic Leukaemia Cells. British Journal of Haematology, 152, 295-306. [Google Scholar] [CrossRef] [PubMed]
[29] Sethi, S., Kumar, S., Lim, K. and Jordan, S.C. (2020) Obinutuzumab Is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney International Reports, 5, 1515-1518. [Google Scholar] [CrossRef] [PubMed]
[30] Gagez, A. and Cartron, G. (2014) Obinutuzumab. Current Opinion in Oncology, 26, 484-491. [Google Scholar] [CrossRef] [PubMed]
[31] Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., et al. (2010) Increasing the Efficacy of CD20 Antibody Therapy through the Engineering of a New Type II Anti-CD20 Antibody with Enhanced Direct and Immune Effector Cell-Mediated B-Cell Cytotoxicity. Blood, 115, 4393-4402. [Google Scholar] [CrossRef] [PubMed]
[32] Klomjit, N., Fervenza, F.C. and Zand, L. (2020) Successful Treatment of Patients with Refractory PLA2R-Associated Membranous Nephropathy with Obinutuzumab: A Report of 3 Cases. American Journal of Kidney Diseases, 76, 883-888. [Google Scholar] [CrossRef] [PubMed]
[33] Hudson, R., Rawlings, C., Mon, S.Y., Jefferis, J. and John, G.T. (2022) Treatment Resistant M-Type Phospholipase A2 Receptor Associated Membranous Nephropathy Responds to Obinutuzumab: A Report of Two Cases. BMC Nephrology, 23, Article No. 134. [Google Scholar] [CrossRef] [PubMed]
[34] Ginthör, N.E., Artinger, K., Pollheimer, M.J., Stradner, M.H. and Eller, K. (2021) Membranous Nephropathy Associated with Immunoglobulin G4-Related Disease Successfully Treated with Obinutuzumab. Clinical Kidney Journal, 15, 564-566. [Google Scholar] [CrossRef] [PubMed]
[35] Hu, X., Zhang, M., Xu, J., Gao, C., Yu, X., Li, X., et al. (2024) Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 19, 1594-1602. [Google Scholar] [CrossRef] [PubMed]
[36] Xu, M., Wang, Y., Wu, M., Chen, R., Zhao, W., Li, M., et al. (2024) Obinutuzumab versus Rituximab for the Treatment of Refractory Primary Membranous Nephropathy. Nephrology Dialysis Transplantation, 40, 978-986. [Google Scholar] [CrossRef] [PubMed]
[37] Jin, X. and Ding, C. (2012) Belimumab—An Anti-Blys Human Monoclonal Antibody for Rheumatoid Arthritis. Expert Opinion on Biological Therapy, 13, 315-322. [Google Scholar] [CrossRef] [PubMed]
[38] Blair, H.A. and Duggan, S.T. (2018) Belimumab: A Review in Systemic Lupus Erythematosus. Drugs, 78, 355-366. [Google Scholar] [CrossRef] [PubMed]
[39] Barrett, C., Willcocks, L.C., Jones, R.B., Tarzi, R.M., Henderson, R.B., Cai, G., et al. (2019) Effect of Belimumab on Proteinuria and Anti-Phospholipase A2 Receptor Autoantibody in Primary Membranous Nephropathy. Nephrology Dialysis Transplantation, 35, 599-606. [Google Scholar] [CrossRef] [PubMed]
[40] Brglez, V., Boyer-Suavet, S. and Seitz-Polski, B. (2020) Complement Pathways in Membranous Nephropathy: Complex and Multifactorial. Kidney International Reports, 5, 572-574. [Google Scholar] [CrossRef] [PubMed]
[41] Ravindran, A., Madden, B., Charlesworth, M.C., Sharma, R., Sethi, A., Debiec, H., et al. (2020) Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 5, 618-626. [Google Scholar] [CrossRef] [PubMed]
[42] Teisseyre, M., Cremoni, M., Boyer-Suavet, S., Ruetsch, C., Graça, D., Esnault, V.L.M., et al. (2022) Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy. Frontiers in Immunology, 13, Article 859419. [Google Scholar] [CrossRef] [PubMed]
[43] Gao, S., Cui, Z. and Zhao, M. (2022) Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 33, 1742-1756. [Google Scholar] [CrossRef] [PubMed]
[44] Appel, G.B., Waldman, M. and Radhakrishnan, J. (2006) New Approaches to the Treatment of Glomerular Diseases. Kidney International, 70, S45-S50. [Google Scholar] [CrossRef] 
[45] Hiepe, F. and Radbruch, A. (2016) Plasma Cells as an Innovative Target in Autoimmune Disease with Renal Manifestations. Nature Reviews Nephrology, 12, 232-240. [Google Scholar] [CrossRef] [PubMed]
[46] Hiepe, F., Dörner, T., Hauser, A.E., Hoyer, B.F., Mei, H. and Radbruch, A. (2011) Long-Lived Autoreactive Plasma Cells Drive Persistent Autoimmune Inflammation. Nature Reviews Rheumatology, 7, 170-178. [Google Scholar] [CrossRef] [PubMed]
[47] Bryer, E., DeStefano, C. and Kazandjian, D. (2022) Current and Prospective Antibody-Based Therapies in Multiple Myeloma. Seminars in Oncology, 49, 41-47. [Google Scholar] [CrossRef] [PubMed]
[48] Stehlé, T., Grimbert, P., Remy, P., Moktefi, A., Audard, V. and El Karoui, K. (2022) Anti-CD38 Therapy for PLA2R-Positive Membranous Nephropathy Resistant to Conventional Immunosuppression. Kidney International, 101, 416-418. [Google Scholar] [CrossRef] [PubMed]
[49] Vink, C.H., van Cranenbroek, B., van der Heijden, J.W., Koenen, H.P.J.M. and Wetzels, J.F.M. (2022) Daratumumab for Multidrug-Resistant Phospholipase-A2 Receptor-Related Membranous Nephropathy. Kidney International, 101, 646-647. [Google Scholar] [CrossRef] [PubMed]